StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast

February 29, 2024 9:00 AM EST | Source: Stock Day Media

Phoenix, Arizona--(Newsfile Corp. - February 29, 2024) - The Stock Day Podcast welcomed StrainsForPains, Inc. (OTC Pink: EBYH) ("the Company"), a medical marijuana recommendation engine that guides patients to the appropriate cannabinoid levels, medical cannabis strains, and consumption methods for their specific ailment. CEO of the Company, Simon Shainberg, joined Stock Day host Matthew Dunehoo.

Dunehoo began the interview by asking about Mr. Shainberg's background. "I am a graduate of the State University of New York (SUNY) where I received my BS in Economics and Business, and I have done graduate studies at MIT. I have twenty years of venture capital experience, and have done successful financings in public companies in areas of scientific technology, health care, CAD/CAM , fashion, merchandising, and real estate. I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's. I developed regenerative medicine systems with stem cell technology in the 1980's working on umbilical cord therapy to treat genetic diseases, cancers, and inherited disorders. In this manner I began to train myself to seek out various treatment options for ailments, whether they be Alzheimers, Parkinsons, Epilepsy, or Osteoarthritis. I am currently a member of the International Cannabinoid Research Society," stated Mr. Shainberg

"What inspired you to create StrainsForPains?" asked Dunehoo. "The inspiration for StrainsForPains comes from a personal need. Around 2007, my son was diagnosed with a brain tumor that required numerous surgeries and drug therapy. That caused him much pain, which had a significant impact on his quality of life. Luckily, his use of opioids to combat the pain was temporary and he soon got off pain meds. Yet, while he was on pain meds I did not know how long it would last. So I delved into the scientific research into medical cannabis to see if that would be an alternative to opioids," said Mr. Shainberg

The conversation then turned to how did you build the medical cannabis database app? "It took a lot of old-fashioned research over 2 decades to create it. I attended cannabis conferences such as the international cannabinoid research society conferences. I bought and read countless books that focused on the medical uses for cannabis, and I took a couple of classes to learn about the endocannabinoid system. I read thousands of clinical studies and peer reviewed journals from Israel to Canada to Germany, taking substantial notes and feeding them into my proprietary computer banks.

StrainsForPains utilizes a robust database of strains, cannabinoids, and medicinal applications aggregated through semantic web technology and validated by medical devices in research centers around the world. I employ advanced artificial intelligence to enhance the system. I believe that we have a service that is rare within this community, in that our competitive advantage is that our competitors do not have the extensive scientific backup to why they suggest taking one cannabinoid over another. I believe that my studies of 10,000 hybrid cannabis plants and its cross reference to over 100 pains are unique within this industry. My observational research also allowed me to gather reliable data that helped me design my system," Mr. Shainberg stated.

"Why do you enter the CBD market?" asked Dunehoo. "My passion comes from my inherent love for the plant, and the ability to improve wellness. Those components compelled me to join the CBD market. Millions of people that do not have chronic pain, but they do suffer from anxiety, depression, insomnia, and moderate pain. They deserve to know about and use CBD, a plant-based alternative to improve their quality of life. I believe that our CBD cream far outpaces the quality of what is out there now in the marketplace due to its high CBD content, manufacturing processes, and other proprietary compounds. Our fundamental approach to product development is extensive R&D, stringent quality control, and adherence to international quality standards. Our initial entry into the market has resulted in $65,000 in wholesale sales to various retail establishments in the tri-state area. We own a 7-acre Pennsylvania facility that will produce and distribute CBD products in 2024."

To close the interview, Mr. Shainberg added that there is a need for innovation beyond our current approaches to mental and physical healthcare and the therapeutic value of these substances is limitless. I am excited to see this movement continue to gain traction and enter mainstream acceptance, with a focus on individualized medicine and how we can alleviate suffering in numerous conditions of the body and mind. In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products. We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app.

To watch Mr. Shainberg's entire interview, please follow this link:

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at

About StrainsForPains, Inc.

Overview of Strainsforpains, Inc.: Please visit our website at Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company's objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. The company owns a 7 acre facility in Pennsylvania that will be used for CBD product production. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society,

Safe Harbor Statement

This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's ability to execute its business plan as anticipated; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy. The words "may" "would" "will" "expect" "estimate" "anticipate" "believe" "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the "Risk Factors" section of the Company's filings with the SEC, which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising these forward-looking statements, except as required by applicable law.

Corporate Social Media

244 Fifth Avenue Suite S242, New York, N.Y. 10001

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
(602) 821-1102

SOURCE: Stock Day Media

To view the source version of this press release, please visit